|
CHARLES CASAMENTO - DIRECTOR |
Mr. Casamento joined our board in March 2017. Since 2007 Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group. He was president and CEO of Osteologix, a start up company which he eventually took public, from October 2004 until April 2007. Mr. Casamento was the founder of Questcor Pharmaceuticals where he was president, CEO and chairman from 1999 through 2004. At Questcor he acquired Acthar, a product whose sales eventually exceeded $1.0 Billion. Eventually Questcor was acquired by Mallinckrodt. At RiboGene Inc. he was president, CEO and chairman from 1993 until 1999 when he merged the company with another company to form Questcor where he continued as CEO and Chairman. He was also co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). Eventually Indevus was acquired by Endo. He has held senior management positions at Genzyme Corporation, where he was Senior Vice President, American Hospital Supply, where he was Vice President of Business Development for the Critical Care division, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He currently sits on the Boards of Directors of First Wave Bio, Relmada Therapeutics, where he is also Chairman, GT Biopharma, PaxMedica, Inc. and Eton Pharmaceuticals. He was previously a director and vice-chairman of the Catholic Medical Missions Board a large not for profit international organization. During his career he has served as a director on the Boards of fifteen public Biotech/Pharma companies. He holds a bachelor's degree in Pharmacy from Fordham University and an M.B.A. from Iona University. |